Integrated Quantitative Investments LLC Purchases Shares of 5,432 Pro-Dex, Inc. (NASDAQ:PDEX)

Integrated Quantitative Investments LLC acquired a new position in shares of Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 5,432 shares of the medical instruments supplier's stock, valued at approximately $254,000. Integrated Quantitative Investments LLC owned about 0.17% of Pro-Dex at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC increased its stake in Pro-Dex by 34.9% during the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after purchasing an additional 1,028 shares during the period. Bank of New York Mellon Corp acquired a new position in Pro-Dex in the fourth quarter valued at approximately $202,000. Trexquant Investment LP acquired a new position in shares of Pro-Dex in the 4th quarter valued at $252,000. Arrowstreet Capital Limited Partnership acquired a new position in Pro-Dex in the fourth quarter valued at $255,000. Finally, American Century Companies Inc. purchased a new position in Pro-Dex during the 4th quarter worth approximately $558,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

Pro-Dex Stock Performance

Shares of NASDAQ:PDEX traded up $2.13 during midday trading on Friday, hitting $63.23. The stock had a trading volume of 55,523 shares, compared to its average volume of 24,131. The company has a market capitalization of $206.19 million, a PE ratio of 31.46 and a beta of 0.40. Pro-Dex, Inc. has a 1 year low of $16.84 and a 1 year high of $65.87. The stock has a 50 day moving average price of $43.65 and a two-hundred day moving average price of $42.27. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, equities analysts predict that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Pro-Dex from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th.

Insider Transactions at Pro-Dex

In other Pro-Dex news, Director Raymond E. Cabillot sold 1,879 shares of the company's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $45.18, for a total value of $84,893.22. Following the sale, the director now owns 352,996 shares of the company's stock, valued at $15,948,359.28. This represents a 0.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 47,953 shares of company stock valued at $2,213,182 in the last quarter. 47.50% of the stock is currently owned by corporate insiders.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.